Oil-soluble polypeptide composition of pure oil system as well as preparation method and application of oil-soluble polypeptide composition

Abstract

The invention relates to the technical field of cosmetics, in particular to an oil-soluble polypeptide composition of a pure oil system as well as a preparation method and application of the oil-soluble polypeptide composition. The composition comprises the following components: palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide diaminobutyryl benzyl amide diacetate, acetyl hexapeptide-8, arginine / lysine polypeptide and grease. Through compounding of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide diaminobutyrylbenzylamide diacetate, acetyl hexapeptide-8 and arginine / lysine polypeptide, the eye cream can balance the structure and function of the skin and special problems of eyes, and has the effects of resisting oxidation and relieving inflammation; the technical problems that an existing eye care product is single in effect, high in irritation and poor in stability are solved, and the purpose of comprehensively improving the periorbital skin is achieved.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, specifically to an oil-soluble polypeptide composition based on a pure oil system, its preparation method, and its application. Background Technology

[0002] As consumers' demands for eye care increase, peptides, due to their strong targeting, small molecular weight, and high safety, are gradually becoming the core active ingredients in eye care products. However, existing technologies have several limitations: First, most peptide raw materials are water-soluble, requiring an aqueous phase system in product formulations, necessitating the addition of preservatives to inhibit microbial growth and increasing the risk of periorbital sensitivity; second, most existing eye care products use emulsification systems, requiring the introduction of surfactants to stabilize the water-oil phase, which can easily damage the periorbital skin barrier and cause irritation; third, single peptide components have limited functionality; fourth, some oil-soluble peptide products contain only 1-2 peptides, lacking synergistic effects between components, and the active ingredients exhibit poor stability and low transdermal efficiency in multiphase systems.

[0003] Chinese invention patent application CN119488465A discloses a dual-anti-inflammatory eye cream and its preparation method, which involves a polypeptide mixture including acetyl hexapeptide-8, acetyl octapeptide-3, acetyl heptapeptide-4, palmitoyl tripeptide-5, and acetyl tetrapeptide-2. This application targets the three main culprits causing eye area problems: skin oxidation, skin glycation, and inflammation. Through multi-segment targeting action, it targets dark circles under the eyes, refines fine lines, and restores elasticity, hydration, and radiance. However, this polypeptide composition is not suitable for use in pure oil systems. Summary of the Invention

[0004] The first aspect of the present invention provides an oil-soluble polypeptide composition of a pure oil system, comprising: palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide diaminobutyryl benzylamide diacetate, acetyl hexapeptide-8, arginine / lysine polypeptide and oil.

[0005] The oil is of plant origin.

[0006] The plant-derived oils include, but are not limited to, at least one of the following: squalane, olive oil (Olea europaea), sweet almond oil (Prunus amygdalus dulcis), grape seed oil (Vitis vinifera), shea butter (Butyros permum parkii), avocado oil (Persea gratissima), rosehip oil (Rosacanina), sunflower seed oil (Helianthus annuus), evening primrose oil (Oenotherabiennis), wheat germ oil (Triticum vulgare), apple seed oil (Malus domestica), meadowfoam seed oil (Limnanthesalba), and jojoba seed oil (Simmondsia sinensis).

[0007] Optionally, the plant-derived oil includes at least one of apple seed oil (Malusdomestica), meadowfoam seed oil (Limnanthesalba), and jojoba seed oil (Simmondsiasinensis).

[0008] Optionally, the weight ratio of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide diaminobutyryl benzylamide diacetate, acetyl hexapeptide-8, and arginine / lysine polypeptide is 1:(0.2-5):(0.8-10):(0.8-10):(0.4-6).

[0009] Optionally, the weight ratio of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide diaminobutyryl benzylamide diacetate, acetyl hexapeptide-8, and arginine / lysine polypeptide is 1:(0.2-2):(0.8-6):(0.8-6):(0.4-4).

[0010] Optionally, the weight ratio of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide diaminobutyryl benzylamide diacetate, acetyl hexapeptide-8, and arginine / lysine polypeptide is 1:(0.5-2):(2-6):(2-6):(1-4).

[0011] This invention utilizes a combination of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide-diaminobutyryl benzylamide diacetate, acetyl hexapeptide-8, and arginine / lysine peptides to balance the effects of skin structure and function, addressing specific eye concerns, and providing antioxidant and soothing anti-inflammatory benefits. Palmitoyl tetrapeptide-7 and palmitoyl tripeptide-1, as core structural regulating peptides, synergistically promote collagen and elastin synthesis in the periocular skin, strengthen the skin barrier function, improve skin elasticity (R2 value), and reduce transepidermal water loss (TEWL), fundamentally improving skin structure and water retention capacity. Dipeptide-diaminobutyryl benzylamide diacetate specifically targets the periocular microcirculation, promoting local blood flow and reducing tissue fluid accumulation, thereby reducing dark circles (increased L value) and puffiness, precisely addressing specific eye concerns. Acetyl hexapeptide-8 inhibits neuromuscular... Through transdermal delivery, it reduces the formation of dynamic wrinkles and forms an antioxidant-soothing closed loop with arginine / lysine peptides. The latter effectively scavenge DPPH free radicals to resist oxidative damage, while the former helps reduce the skin's erythema index and relieve sensitive inflammation around the eyes. When the five peptides are combined in a specific ratio, their efficacy targets are complementary and there is no antagonistic effect. Combined with the pure oil system (plant oil carrier) to enhance transdermal efficiency and ingredient stability, it ultimately achieves a balanced and synergistic effect across four dimensions: skin structure repair, improvement of eye problems, antioxidant and soothing anti-inflammatory properties, comprehensively optimizing the condition of the skin around the eyes.

[0012] The second aspect of the present invention provides a method for preparing an oil-soluble polypeptide composition in a pure oil system, comprising the following steps: heating an oil, and sequentially adding palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide diaminobutyryl benzylamide diacetate, acetyl hexapeptide-8, and arginine / lysine polypeptide to the oil; stirring until completely dissolved, cooling and filtering to obtain the oil-soluble polypeptide composition.

[0013] Optionally, the heating temperature is 40-45°C.

[0014] A third aspect of the present invention provides an application of an oil-soluble polypeptide composition based on a pure oil system in the preparation of eye care products.

[0015] Optionally, the eye care product is at least one of eye cream, eye serum, or eye mask.

[0016] Beneficial effects 1. This invention, through the combination of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide diaminobutyryl benzylamide diacetate, acetyl hexapeptide-8, and arginine / lysine polypeptide, can balance the effects of skin structure and function, special eye problems, and anti-oxidation and soothing anti-inflammatory.

[0017] 2. By limiting the weight ratio of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide diaminobutyryl benzylamide diacetate, acetyl hexapeptide-8, and arginine / lysine polypeptide to 1:(0.2-5):(0.8-10):(0.8-10):(0.4-6), the stability of the pure oil system can be improved, and user satisfaction during use can be increased.

[0018] 3. The pure oil system constructed by the present invention, consisting of plant oils and oil-soluble peptides, enhances the efficacy and stability of peptides.

[0019] 4. The oil-soluble polypeptide composition of the present invention solves the technical problems of existing eye care products, such as single efficacy, high irritation and poor stability, and achieves the goal of comprehensively improving the skin around the eyes.

[0020] 5. The oil-soluble polypeptide composition of the present invention is applicable to a variety of oils and fats. Attached Figure Description

[0021] Figure 1 This is the raw material composition of the soothing and rejuvenating peptide.

[0022] Figure 2 It is the raw material composition of oil-soluble reverse-time peptides. Detailed Implementation

[0023] Example 1, Comparative Examples 1-4 An oil-soluble polypeptide composition based on pure oil, the components of which are shown in Table 1 by weight percentage: Table 1

[0024] The apple seed oil is sourced from OShiNatural, a natural European plant-based source. The raw material composition of the soothing and rejuvenating peptide is as follows: Figure 1 As shown, the raw material composition of the oil-soluble time-reversing peptide is as follows: Figure 2 As shown.

[0025] The preparation methods of Examples 1, Comparative Examples 1, Comparative Examples 2 and 4 are as follows: After heating the oil (42°C), the remaining components are added to the oil; the mixture is stirred until completely dissolved, cooled and filtered to obtain an oil-soluble polypeptide composition.

[0026] Comparative Example 3: A method for preparing an oil-soluble polypeptide composition in a pure oil system, comprising the following steps: preparation using a conventional O / W emulsification process.

[0027] Phase A (oil phase): Apple seed oil: 15.0% Emulsifiers (such as cetearyl oleate, sorbitan oleate): 3.0% Emollients (such as caprylic / capric triglycerides): 5.0% Phase B (aqueous phase): Deionized water: Add to 100% Glycerin (humectant): 5.0% Thickener (such as xanthan gum): 0.2% C phase (added later): Preservatives (such as phenoxyethanol, ethylhexylglycerin): 0.8% Neutralizing agent (such as triethanolamine, used to adjust pH): appropriate amount Preparation method: Oil phase: Place all components of phase A (apple seed oil, emulsifier, emollient) in an oil phase pot, heat to 75-80℃, and stir until completely dissolved and homogeneous.

[0028] Aqueous phase: Place the components of phase B (deionized water, glycerin, thickener) in an aqueous phase pot, heat to 75-80℃, and stir until the thickener is completely dispersed and dissolved, and the system is homogeneous and free of particles.

[0029] Emulsification: While homogenizing (approximately 2000-3000 rpm), slowly add phase A to phase B. After the addition is complete, maintain this temperature and speed for 5-8 minutes to homogenize and form a preliminary emulsion.

[0030] Stirring and cooling: Keep the stirrer running while cooling begins. When the temperature drops below 45°C, add phase C (preservatives, etc.) and stir until homogeneous.

[0031] Addition of active ingredients: When the temperature drops below 40°C, add “Soothing and Rejuvenating Peptide” and “Oil-soluble Anti-aging Peptide” in sequence while stirring slowly to ensure that they are fully dispersed in the emulsion.

[0032] Continue stirring and cooling to below 35°C. Take a sample for testing and adjust the pH to 5.5-6.5. Finally, filter and discharge to obtain the O / W emulsion.

[0033] Performance testing methods and data The oil-soluble peptide compositions prepared in the examples and comparative examples were subjected to performance tests.

[0034] 1. Improvement of skin structure and function Test method: According to GB / T38916-2020 "Specifications for Efficacy Evaluation of Cosmetics", the following instruments and methods were used: Fine line depth: The VISIA skin analysis system (Canfield Scientific, USA) performs high-resolution imaging of the corner of the eye area to analyze changes in fine line depth.

[0035] Skin elasticity (R2): Cutometer MPA580 (Courage+Khazaka, Germany) was used to measure the total elasticity (R2) of the skin around the eyes.

[0036] Skin barrier function (TEWL): Tewameter™ 300 (Courage+Khazaka, Germany) measures transepidermal water loss (TEWL).

[0037] Skin moisture content: Corneometer CM825 (Courage+Khazaka, Germany), measures stratum corneum moisture.

[0038] All indicators were measured before use and 8 weeks later, and the percentage improvement was recorded.

[0039] The test results are shown in Table 2: Table 2

[0040] Conclusion: Example 1 is superior to the comparative examples in terms of improvement in fine lines, elasticity, barrier function, and moisture.

[0041] 2. Improvement of specific eye problems Test method: Dark circles lighten: Use a colorimeter (Minolta CR-400) to measure changes in the L value (brightness) of the under-eye area. An increase in the L value indicates that dark circles have lightened.

[0042] Improvement of puffiness: 3D skin imaging system (PRIMOS) analyzes changes in the volume of puffiness around the eyes.

[0043] Microcirculation enhancement: Laser Doppler flowmeter (PeriFluxSystem5000) measures blood flow in the superficial layer of skin around the eyes.

[0044] All indicators were measured before use and 8 weeks later, and the percentage improvement or L value increase was recorded.

[0045] The test results are shown in Table 3: Table 3

[0046] Conclusion: Example 1 showed the best performance in reducing dark circles, puffiness, and improving microcirculation.

[0047] 3. Antioxidant and soothing anti-inflammatory properties Test method: Antioxidant capacity: DPPH free radical scavenging rate, determined in vitro according to GB / T5009.232-2016 standard, was used to measure the DPPH free radical scavenging rate of the sample.

[0048] Soothing and anti-inflammatory: Mexameter MX18 (Courage+Khazaka, Germany) measures the erythema index of the skin around the eyes, reflecting the soothing and anti-inflammatory effect.

[0049] The test results are shown in Table 4: Table 4

[0050] Conclusion: Example 1 showed significantly better antioxidant and soothing anti-inflammatory effects than the comparative example.

[0051] 4. Component stability Test method: The samples were placed in a 40℃ constant temperature chamber for accelerated aging for 3 months. The content of the main active ingredients (such as peptides, astaxanthin, etc.) was detected by high performance liquid chromatography (HPLC), and the content retention rate was calculated.

[0052] Reference standard: GB / T24800.8-2009 Determination of polypeptide components in cosmetics by high performance liquid chromatography.

[0053] The test results are shown in Table 5: Table 5

[0054] Conclusion: The active ingredient in Example 1 exhibits the best stability.

[0055] 5. User satisfaction Test method: A standardized questionnaire was used to investigate the product's performance, including feedback on fine lines, dark circles, puffiness, and overall comfort. Participants rated the product on a scale of 0 to 10.

[0056] Reference standards: GB / T38916-2020, industry practices.

[0057] The investigation will be conducted uniformly eight weeks later.

[0058] The test results are shown in Table 6: Table 6

[0059] Conclusion: Example 1 achieved the highest user satisfaction.

[0060] The comparison of test data in Table 2-6 clearly shows that: The three peptides showed a significant synergistic effect: Example 1 (containing three peptides) was significantly better than Comparative Example 1 (single peptide) and Comparative Example 4 (two peptides) in all efficacy indicators, demonstrating the synergistic effect of the three peptides. Example 1 is superior to Comparative Example 2 (different peptide combinations), demonstrating that the specific three peptide combinations selected in this invention have the best synergistic effect; Example 1 is superior to Comparative Example 3 (emulsified system), demonstrating that the pure oil system enhances the efficacy of peptides and protects their stability; Example 1 received the highest user satisfaction score, indicating that this invention not only performs well in objective test indicators but also has significant advantages in subjective user experience.

[0061] In summary, the technical solution of this invention, through the synergistic effect of three specific oil-soluble peptides and the carrier design of a pure oil system, successfully solves the technical problems of existing eye care products, such as single efficacy, high irritation, and poor stability, and achieves the goal of comprehensively improving the skin around the eyes.

Claims

1. An oil-soluble polypeptide composition in a pure oil system, characterized in that, The components include: palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide diaminobutyryl benzylamide diacetate, acetyl hexapeptide-8, arginine / lysine peptides, and lipids.

2. The oil-soluble polypeptide composition of the pure oil system according to claim 1, characterized in that, The oil is a plant-derived oil.

3. The oil-soluble polypeptide composition of the pure oil system according to claim 2, characterized in that, The plant-derived oils include at least one of apple seed oil, meadowfoam seed oil, and jojoba seed oil.

4. The oil-soluble polypeptide composition of the pure oil system according to claim 1 or 3, characterized in that, The weight ratio of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide diaminobutyryl benzylamide diacetate, acetyl hexapeptide-8, and arginine / lysine polypeptide is 1:(0.2-5):(0.8-10):(0.8-10):(0.4-6).

5. The oil-soluble polypeptide composition of the pure oil system according to claim 4, characterized in that, The weight ratio of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide diaminobutyryl benzylamide diacetate, acetyl hexapeptide-8, and arginine / lysine polypeptide is 1:(0.2-2):(0.8-6):(0.8-6):(0.4-4).

6. The oil-soluble polypeptide composition of the pure oil system according to claim 5, characterized in that, The weight ratio of the palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide diaminobutyryl benzylamide diacetate, acetyl hexapeptide-8, and arginine / lysine polypeptide is 1:(0.5-2):(2-6):(2-6):(1-4).

7. A method for preparing an oil-soluble polypeptide composition of a pure oil system according to any one of claims 1-6, characterized in that, Includes the following steps: The oil was heated, and palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, dipeptide diaminobutyryl benzylamide diacetate, acetyl hexapeptide-8, and arginine / lysine polypeptide were added to the oil in sequence. The mixture was stirred until completely dissolved, cooled, and filtered to obtain an oil-soluble polypeptide composition.

8. A method for preparing an oil-soluble polypeptide composition of a pure oil system according to any one of claims 7, characterized in that, The heating temperature is 40-45℃.

9. The application of the oil-soluble polypeptide composition of the pure oil system according to any one of claims 1-6, characterized in that, Used in the preparation of eye care products.

10. The application of the oil-soluble polypeptide composition of the pure oil system according to claim 9, characterized in that, The eye care product is at least one of eye cream, eye serum, or eye mask.

Images